Dr. Peter Martin On Future Treatment Options for Mantle Cell Lymphoma

In this video from OncLive, Dr. Peter Martin discusses potential changes in the future treatment of younger patients with mantle cell lymphoma (MCL), as well as new lines of therapy currently being developed for all patients with MCL. These new therapies include Bruton’s tyrosine kinase inhibitors, PI3 kinase inhibitors, Bcl-2 inhibitors, immunomodulatory drugs, and immunotherapy agents.

In the Lymphoma Program our patient care is informed by our clinical research. A full listing of available trials for MCL can be found on our clinical trials website.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Google photo

You are commenting using your Google account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s